Genetics of perioperative pain management by Packiasabapathy, Senthil et al.
Genetics of perioperative pain management
Senthil Packiasabapathy, Nicole Horn, Senthilkumar Sadhasivam
Department of Anesthesia, Riley Hospital for Children at Indiana University Health, Indianapolis, 
Indiana, USA
Abstract
Purpose of review—The current review will discuss the current literature on genetics of pain 
and analgesia, with special emphasis on perioperative setting. We will also discuss 
pharmacogenetics-based management guidelines, current clinical status and future perspectives.
Recent findings—Recent literature suggests that the interindividual variability in pain and 
postoperative analgesic response is at least in part because of one’s genetic make-up. Some of the 
well characterized polymorphisms that are associated with surgical pain and opioid-related 
postoperative adverse outcomes are described in catechol-O-methyl transferase, CYP2D6 and μ-
opioid receptor (OPRM1), ATP-binding cassette subfamily B member 1, ABCC3, organic cation 
transporter 1 genes. Clinical Pharmacogenetics Implementation Consortium has put forth 
recommendations on CYP2D6 genotype-based opioid selection and dosing. The list of drug–gene 
pairs studied continue to expand.
Summary—Pharmacogenetic approach marks the dawn of personalized pain medicine both in 
perioperative and chronic pain settings.
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INTRODUCTION
The past decade has seen tremendous increase in the volume of research on genetics of 
nociception and analgesia, after the completion of the human genome project. Though 
genetic factors play a major role in the robust interindividual variability in nociception, the 
pain experience itself is influenced by a number of other factors such as mood, behavior, 
expectations, past life experiences, sex and other psychosocial and environmental factors. 
Understanding the role of genetics is a first and the most essential step toward explaining the 
disparity in pain threshold and tolerance and in susceptibility to chronic pain, besides 
explaining interindividual variations in analgesia and adverse outcomes. It also opens up the 
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door for exploring the possibility of personalized analgesic interventions to improve surgical 
pain relief while avoiding adverse effects.
The current review will give an overview of the genetics of nociception, relevant to 
perioperative pain, chronic postoperative pain and pharmacogenetics of analgesic drugs.
PAIN AND GENOMICS
Nociception involves a number of components including the nociceptors, inflammatory 
mediators, nociceptive, antinociceptive and pain modulating neuronal pathways and the 
respective neurotransmitters, ion channels on the neurons, receptors of the neurotransmitters 
and the second messenger systems to name a few. They serve to transduce, conduct and 
modulate noxious stimuli. Pain is a subjective, emotional experience, resulting from the 
complex processing of the noxious stimulus in the pain matrix of the brain. A number of 
genetic polymorphisms have been described in the above components, resulting in a wide 
range of variability. Functional pain genomics is the study of genetic basis of pain 
experience. This includes genetics of nociception, heritable pain conditions like 
erythromelalgia, congenital insensitivity to pain etc., chronic pain conditions as well as 
genetic basis of psychological factors that define the pain experience.
Pain perception
Catecholamines like epinephrine, nor-epinephrine and dopamine play a pivotal role in pain 
transmission and modulation. Catechol-O-methyl transferase (COMT) is the enzyme 
involved in degradation of catecholamines. Decreased activity of COMT results in higher 
levels of catecholamines, therefore, increased sensitivity to pain [1,2]. Elevated dopamine 
levels cause a depletion of enkephalins, leading to an upregulation of opioid receptors, 
causing increased temporal summation and heightened pain sensitivity [3]. Increased levels 
of epinephrine and the subsequent stimulation of β2/3 receptors has also been described [4]. 
Three haplotypes [low pain sensitivity (LPS), average pain sensitivity and high pain 
sensitivity (HPS)] have been described based on the four common single nucleotide 
polymorphisms (SNPs) of the gene coding for COMT [2]. The COMT polymorphisms are 
found to influence RNA stability and protein translation [5,6]. The LPS phenotype exhibited 
the highest COMT activity and HPS the lowest. Even a single LPS haplotype has been found 
to decrease risk of temporomandibular joint disorder [2], postoperative pain and also affect 
opioid consumption [7,8]. In a study of postoperative pain and opioid consumption in 
children undergoing adenotonsillectomy, minor allele carriers were found to have 
significantly greater analgesic requirement compared with homozygotes of major alleles [9].
Polymorphisms in OPRM1 gene, have been known to alter experimental pain sensitivity by 
affecting the μ-opioid receptor function [10]. OPRM1 SNPs also influence postoperative 
pain [8] and opioid requirements in chronic pain conditions [11]. Sexual dimorphism in heat 
pain sensitivity secondary to SNPs in OPRD1 gene coding for δ-opioid receptors has been 
reported [12].
Guanosine Triphosphate (GTP) cyclohydrolase 1 is the rate limiting enzyme in the synthesis 
of tetrahydrobiopterin (BH4), which is an essential cofactor in the formation of pain 
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modulators like serotonin, dopamine, nor-epinephrine, epinephrine and nitric oxide. 
Existence of a specific haplotype of GCH1 gene encoding for GTP cyclohydrolase 1 with 
lower levels of enzyme activity, has been shown to decrease experimental pain sensitivity 
and also decrease the levels of pain after lumbar discectomy for radicular lower back pain 
[13]. The protective haplotype is associated with delayed need for opioid therapy for cancer 
pain [14]. Research on the role of BH4 blocking drugs as potential analgesics is ongoing 
[15]. Sulfasalazine decreases levels of BH4 and has been proposed for neuropathic pain [16].
Polymorphisms associated with variation in pain sensitivity have been reported in genes 
coding for melanocortin 1 receptor (MC1R) [17], transient receptor potential V1 [12], 
transient receptor potential A1, monoamine oxidase, serotonin transporter (SLC6A4), 
norepinephrine transporter (SLC6A2) [18] and fatty acid amide hydrolase [19] among 
others.
Inflammation is an important response to trauma that contributes to pain. Hence it is 
intuitive that genetic variants in inflammatory mediators result in varying pain perception 
and analgesia. For instance, IL-1 plays a critical part in postincision pain [20]. 
Polymorphisms of IL-1 receptor antagonist gene causing a lower concentration of the 
antagonist, results in higher postoperative opioid consumption [7].
Chronic postsurgical pain
Pain lasting for 3 months or more after surgery is called chronic postsurgical pain (CPSP). 
This is encountered by 15–30% of the surgical population and may last lifelong in some 
[21,22]. The role of genetic polymorphisms and epigenetic modifications have been 
suggested in persistence of pain beyond the duration of tissue healing. For instance, COMT 
polymorphisms have been associated with development of CPSP [23,24]. A variant of 
protein kinase C alpha gene (PRKCA) has been reported in patients suffering from 
neuropathic pain following knee arthroplasty [25]. It is remarkable that PRKCA has been 
associated with long-term potentiation and synaptic plasticity [21].
Epigenetics and acute to chronic transition of pain
Epigenetics refers to the modification of gene expression under environmental influence, 
that does not alter the gene sequence itself. DNA methylation and histone deacetylation are 
some examples. There is evidence suggesting the role of epigenetic modification in the 
development of CPSP [21]. Drugs targeting epigenetic modifications like zebularine (DNA 
methyltransferase inhibitor) and valproic acid (histone deacetylase inhibitor) are being 
studied for pain [26,27].
Psychosocial factors, race and sex
A number of factors, other than genotype per-se, moderate the ‘gene-pain’ relation. For 
instance, advancing age appears to decrease the influence of pain-specific genotype on 
actual pain experience, as environmental factors play a greater role with age [28,29]. 
Psychological factors have a big part to play in pain perception. Polymorphism in serotonin 
receptor genes 5HTR1A and 5HTR2A have been related to postoperative pain and 
depression [30]. Haplotype variants ADRB2 gene coding for β2-adrenergic receptors have 
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been related to a number of pain-related psychologic and physiological phenotypes. A 
certain variant has been related to positive psychological characteristics such as lower levels 
of anxiety and somatization and lower risk of chronic pain [31].
Experimental pain models indicate unequal burden of pain in different races [32,33■]. In a 
prospective trial of children undergoing tonsillectomy, it was found that African-American 
children had greater postoperative pain and white children had higher incidence of opioid-
related adverse events [34]. Though genetic differences are known to play a role [35], it is 
not quite clear about the relative contributions of genetic, socioenvironmental factors and 
past life experiences.
Many studies examining the sex difference in pain point toward greater sensitivity to 
experimental pain, higher prevalence of chronic pain and higher postoperative pain in 
women [36,37]. Though a number of factors are known to contribute to this difference, 
genetic dimorphism plays a major role. The best characterized dimorphism being the MC1R 
gene coding for melanocortin receptor. Certain allelic variants of the MC1R significantly 
improve κ-opioid analgesia in red-haired women compared with the men counterparts [17].
PHARMACOGENETICS
Pharmacogenetics is the study of genetic variations affecting individual drug response. This 
includes genetic factors influencing the pharmacokinetics and pharmacodynamics of the 
drug. Genetic variations can be observed in the metabolism of drugs (pharmacokinetics) or 
at the site of action of the drug (pharmacodynamics).
Opioids
Polymorphisms have been described in enzymes involved in opioid metabolism, various 
transporters as well as opioid receptors. Like most other drugs, opioids undergo phase I 
metabolism mediated by the cytochrome P450 (CYP) family of enzymes. Some of the 
prodrugs are converted to their active forms and some are inactivated by CYP enzymes. 
Codeine is a prodrug that undergoes CYP2D6 mediated O-demethylation to produce its 
active form, morphine. There are more than 100 alleles of CYP2D6 described, with varying 
population frequencies [38,39]. They can be classified into four broad phenotypes: 
ultrarapid, extensive, intermediate and poor metabolizers [40]. Poor metabolizers show 
substandard analgesic response to codeine due to low levels of morphine, and ultrarapid 
metabolizers exhibit excessive and significant adverse events including respiratory 
depression, in response to codeine. Cases of respiratory depression and death after codeine 
administration have been reported, especially in children and breast-fed infants of ultrarapid 
metabolizer mothers taking codeine [41–44].
Tramadol is another CYP2D6 substrate, to form O-desmethyl tramadol, which is more active 
on μ-opioid receptor (MOR) than tramadol. CYP2D6 polymorphism markedly affects the 
safety and anal-gesic efficacy of tramadol [45,46]. Respiratory depression has been reported 
in ultrarapid metabolizers after tramadol administration [47].
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Reports of mortality after codeine and tramadol has led the food and drug administration 
(FDA) to issue warnings against the use of tramadol and codeine in all children less than 12 
years, children less than 18 years with obstructive sleep apnea (OSA), obesity or chronic 
lung disease and after adeno-tonsillectomy and also in breast-feeding mothers [48■■].
Methadone is administered as a racemic mixture of (R)-enantiomers and (S)-enantiomers, 
with the (R)-accounting for the majority of the opioid effect and the (S)-enantiomer 
responsible for adverse effects [49,50]. CYP2B6 primarily metabolizes methadone to the 
inactive metabolite 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine. CYP3A4 and CYP2D6 
have also been shown to be involved in methadone metabolism. The CYP2B6 gene is highly 
polymorphic with over 38 variants identified to date [51]. CYP2B6*6 is the most common 
and clinically relevant allele, with a markedly reduced hepatic expression and activity [52]. 
Carriers of this allele, particularly homozygotes exhibit slower elimination increasing risk of 
overdose after administration [53] (Table 1).
Fentanyl, alfentanil and sufentanil metabolism are subject to genetic variability in the 
CYP3A system [54,55].
Uridine diphosphate glucuronosyltransferase (UGT) is a phase II enzyme, and morphine is 
subject to conjugation by UGT2B7. Morphine-3-glucuronide is the major metabolite, and 
morphine-6-glucuronide is the more active, minor metabolite [56]. Polymorphism in the 
UGT enzyme and variable response to morphine have been reported [3,57]. ATP-binding 
cassette subfamily B member 1 (ABCB1), also known as multidrug resistance 1 is an efflux 
protein that determines the quantity of morphine reaching the central nervous system and 
binding to MOR. Variable response to morphine has been reported secondary to 
polymorphisms in ABCB1 gene and OPRM1 gene coding for MOR [10,58–60]. Organic 
cation transporter 1 (OCT1) mediates hepatocellular uptake of morphine [61] (Table 1).
Genetic polymorphisms have been studied in OCT1 gene. There is evidence of decreased 
clearance of O-desmethyl tramadol in patients with decreased OCT1 activity, leading to 
higher plasma concentration and improved analgesic efficacy [62].
Nonfunctional variants of melanocortin (MC1R) gene, which results in red hair, are 
associated with sexual dimorphism in κ-opioid analgesia. Red-haired women with certain 
MC1R variants are known to require a lesser dose of pentazocine compared with red-haired 
men [17,63].
OPRM1 polymorphism has been studied to influence fentanyl dose requirements after 
orofacial surgery and intrathecal fentanyl doses for labor analgesia [64–66]. κ-agonist such 
as buprenorphine may be used instead of a μ-agonist such as morphine in patients with an 
inactive OPRMI allele [67]. Variable response to remifentanil has been documented 
secondary to polymorphism in serotonin transporter (5-HTT) [68].
NSAIDs
NSAIDs are predominantly metabolized by the CYP2C9 enzyme system. Poor metabolizers 
with lower CYP2C9 enzyme activity show decreased clearance and high incidence of 
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adverse events like gastro-intestinal bleeding [69,70]. The bleeding risk rises several-fold 
when warfarin, another CYP2C9 substrate is coadministered in these patients [71]. 
Celecoxib, a cyclo-oxygenase 2 (COX-2) inhibitor is a substrate of CYP2C9 enzyme and 
high plasma concentrations have been reported in poor metabolizers [72]. FDA has issued 
drug label suggesting dose reduction or alternative therapy based on CYP2C9 status, 
considering the high risk of cardiovascular and gastrointestinal side effects in poor 
metabolizers [73]. For poor metabolizers, treatment with NSAIDs should start at half the 
lowest recommended dose to avoid adverse cardiovascular and gastrointestinal events [67]. 
Parecoxib is a prodrug that is converted to its active form valdecoxib by the polymorphic 
CYP3A enzyme system [39].
NSAIDs act through inhibition of COX-1 and COX-2 enzymes, that are coded by 
prostaglandinendoperoxide synthase (PTGS) 1 and 2, respectively [74]. Patients with 
increased expression of PTGS 2 may have better analgesic response to COX-2-specific 
agents like celecoxib, valdecoxib etc. compared with nonspecific NSAIDs.
Local anesthetics
Regional techniques are a preferred modality of perioperative analgesia, favored for their 
superior analgesia with minimal adverse effects. Local anesthetics act by blocking sodium 
channels and mutations in SCN9A channels coding for sodium channels have been shown to 
demonstrate resistance to lidocaine [75]. Genetic variability has also been associated to risk 
of local anesthetics toxicity. MC1R variants with decreased lidocaine efficacy has also been 
described [76].
CLINICAL APPLICATION AND RECOMMENDATIONS
Clinical implementation of pharmacogenetics in pain remains limited due to a number of 
barriers that include inexperience, accessibility and cost of genetic testing and lack of 
integration of genetic test results to clinical decision support in electronic medical records. 
Nevertheless, the slow translation of pharmacogenomics into clinical practice is evident 
from the fact that the FDA had issued warnings and drug inserts increasingly contain dosing 
statements based on the patient’s genetic makeup.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has put forth dosing 
guidelines for a number of drugs, and one of the most prominent examples relevant to pain 
medicine is CYP2D6 status and dosing of opioids like codeine and tramadol [77] (Table 2). 
Drug–gene pairs are systematically classified into various CPIC levels based on the strength 
of evidence. CPIC level ‘A’ denotes that ‘genetic information should be used to change 
prescribing of affected drug’ and level ‘B’ denotes that ‘genetic information could be used to 
change prescribing of the affected drug because alternative therapies/dosing are extremely 
likely to be as effective and as safe as nongenetically based dosing’ [78].
Table 2 shows the CPIC recommendations for codeine and tramadol [77]. Since weak 
opioids like codeine and tramadol form the second step of the WHO pain management 
ladder, an alternative therapy in ultrarapid metabolizer or poor metabolizer would constitute 
a step up to morphine or step down to NSAIDs. A monitored trial of oxycodone and 
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hydrocodone could be viable alternatives in these patients because, despite being CYP2D6 
substrates to a smaller extent, they also have analgesic activity of their own [79■]. CPIC 
guidelines are not yet available for oxycodone, celecoxib and metha-done despite CPIC level 
A or B.
CONCLUSION
As regulatory bodies advocate the use of genetic information in patient management and 
genetic testing becomes widely available and affordable, the era of personalized 
perioperative analgesia is on the horizon, especially with growing literature on surgical pain, 
CPSP and opioid analgesia/adverse effects. A good starting point would be to target the 
high-risk population [80■]. As far as opioids are concerned, high risk population would 
comprise of small children, breast-feeding women, patients with generally increased risk of 
respiratory depression such as those with OSA, chronic lung disease, children undergoing 
adeno-tonsillectomy and ethnic groups with extremely high prevalence of certain 
polymorphisms and genetic variations. For instance, CYP2D6 ultrarapid metabolizer status 
is as high as 30% in Ethiopians (compared with ~1% in whites); the Surui Indians of the 
Amazon are$said to have greater than 80% prevalence of homozygous carriers of reduced 
activity allele of OCT1 [62]. Pharmacogenetics being a science of outliers, genetic testing 
and reporting of patients at higher risk for an unexpected and significant adverse event to an 
analgesic in the perioperative period would contribute to the growing body of evidence. 
Large multicenter randomized controlled trials in perioperative setting, with standardized 
and sensitive outcome measures are also an essential step toward personalized pain 
medicine.
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KEY POINTS
• Pain is a complex subjective phenomenon with a wide range of variability.
• Genetic variations play important part in a person’s pain experience and 
response to perioperative analgesic therapy.
• Pharmacogenetics of perioperative analgesics (especially opioids) may 
explain ineffective analgesia in some while excessive adverse events in others.
• Understanding genetic contributions to interindividual variability will help 
tailor perioperative pain management and optimize outcomes.
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